APLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Applied Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Applied Therapeutics says it received FDA's warning letter for genetic disease drug study
Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after the U.S. health regulator declined to approve the treatment last week.
Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.
The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.
Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug
Applied Therapeutics (APLT) shares cratered Friday as the biopharmaceutical firm reported that the Food and Drug Administration (FDA) rejected its application for its experimental treatment for a rare metabolic disease known as Galactosemia.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Applied Therapeutics, Inc. (APLT) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
On Wednesday, Applied Therapeutics, Inc APLT received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat for Classic Galactosemia.
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
US FDA declines to approve Applied Therapeutics' genetic disease drug
The U.S. Food and Drug Administration on Wednesday declined to approve Applied Therapeutics' drug to treat galactosemia, a rare genetic metabolic disease, the company said.
Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know
Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
